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http://dxObjective: Bronchiolitis obliterans syndrome (BOS) is the main long-term complication limiting survival after
lung transplantation. There exists no cure for BOS and its mechanisms are not well understood. Early identifi-
cation of BOS could therefore contribute to improvement of therapeutic and preventive measures. The human
chitinase-like glycoprotein YKL-40 is involved in regulation of inflammatory tissue response and remodeling
and is associated with pulmonary fibrosis. However, its role in BOS is unknown.
Methods: A total of 57 recipients with irreversible fibrotic BOS and matched 85 recipients without BOS were
retrospectively analyzed. Pretransplant serum samples were available at the time of the study. Serum and bron-
choalveolar lavage samples were obtained at BOS diagnosis or at a comparable time point in patients without
BOS. Additionally, serum samples were obtained 3 months later after BOS diagnosis or after the first sample in
patients without BOS. YKL-40 concentrations were analyzed by enzyme-linked immunosorbent assay.
Results: Pretransplant serum YKL-40 concentrations were higher in recipients who developed BOS and were
useful in identifying patients at high risk for BOS development (odds ratio, 1.3; 95% confidence interval,
1.01-1.9; P ¼ .02). At BOS diagnosis, posttransplant YKL-40 concentrations were significantly elevated in
the serum and bronchoalveolar lavage of patients with BOS compared with those without BOS at a comparable
posttransplant time point. Of note, there was no significant association between serum YKL-40 concentrations
and the frequency of acute rejection episodes.
Conclusions: Elevated pretransplant serum YKL-40 concentration is associated with BOS development and
could be an independent biomarker in early prediction and monitoring of BOS. (J Thorac Cardiovasc Surg
2014;148:273-81)T
XBronchiolitis obliterans syndrome (BOS) is the major
long-term complication in lung allograft recipients within
the first 5 years posttransplant.1 BOS is associated with
poor survival and accounts for more than 30% of all
deaths after the third posttransplant year.1,2 At cellular
level, BOS is characterized by patchy submucosal
fibrosis of the respiratory bronchioles that results in the
occlusion of the airway lumen, resulting in deteriorating
pulmonary function and decrease of the forced
expiratory volume in 1 second (FEV1).
3,4 Pulmonary
function testing is the main clinical tool used in
diagnosing BOS. In addition, transbronchial biopsy
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The Journal of Thoracic and Cadeterioration. However, its sensitivity for BOS diagnosis
is low, due to the nonuniform distribution of fibrosis and
airway involvement. Thus, transbronchial biopsy might
deliver false negative histology results despite declining
pulmonary function.
Based on the above reasoning, it becomes clear that early
identification of BOS and/or risk factors that might
contribute to its development in lung transplant recipients
by using noninvasive markers might contribute to the devel-
opment of novel therapeutic or even preventive strategies
for BOS. The current dogma in BOS pathogenesis is that
repeated injuries to the allograft by ischemic reperfusion,
acute rejection, inflammation, alloreactivity directed to-
ward human leukocyte antigens, reflux, air pollution, and
infections; particularly cytomegalovirus (CMV) infection
and pseudomonal colonization may contribute to the dis-
ease development.3-6 These assaults are followed by
responsive neutrophil and lymphocyte infiltration of the
allograft with secondary activation of various cytokines
and chemokines that contribute to inflammatory cell
infiltration and BOS progression.7
We recently reported that circulating endothelin (ET)-1
concentrations might be predictive in BOS diagnosis8; how-
ever, ET-1 was confounded by its association with acute
allograft rejection in the patient cohort studied. The humanrdiovascular Surgery c Volume 148, Number 1 273
Abbreviations and Acronyms
BAL ¼ bronchoalveolar lavage
BOS ¼ bronchiolitis obliterans syndrome
CMV ¼ cytomegalovirus
ET ¼ endothelin
FEV1 ¼ forced expiratory volume in 1 second
IL ¼ interleukin
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Xchitinase-like glycoprotein YKL-40 is expressed and
secreted by lung alveolar macrophages, neutrophils, and
epithelial cells9,10 and is associated with chronic
obstructive pulmonary disease, lung fibrosis, and
asthma.10-12 Of note, high serum YKL-40 levels are associ-
ated with poor survival in patients with idiopathic pulmo-
nary fibrosis.11 In line with this, animal models indicate
that YKL-40 is a prominent regulator of lung inflammation
and remodeling.13 Therefore, we hypothesized that
YKL-40 might also play a role in BOS.
PATIENTS AND METHODS
Patients
This study was approved by the Ethics Committee of the Medical Uni-
versity of Vienna. A total of 57 recipients with irreversible fibrotic BOS
and matched 85 recipients without BOS, who underwent lung transplan-
tation between 2006 and 2008 and gave informed consent to participate
were enrolled. Table 1 summarizes the demographic and the most rele-
vant clinical characteristics of the study patients. Recipient consecutive
pretransplant serum samples, which had been obtained shortly before
transfer into the operating room, were available in our serum bank at
the time of our study. Serum and bronchoalveolar lavage (BAL) samples
were obtained at BOS diagnosis during the routine clinical surveillance
(Table 1). Serum and BAL samples were obtained from patients with
BOS grade 0 at a time point comparable to the time of BOS diagnosis
in BOS group. Additionally, serum samples were obtained 3 months later
after BOS diagnosis or after the first sample in patients with BOS grade
0. A total of 15 nonsmoking, healthy individuals who had no signs of pul-
monary disorders and gave informed consent to participate served as
additional controls. All samples were coded and snap frozen until use.
All patients were routinely followed weekly during the first 3 weeks,
monthly in the first year, every 2 months during the second year post-
transplant, or when clinically indicated. The surveillance protocol
included the history, physical status, pulmonary function, blood tests,
and bronchoscopy with transbronchial biopsies and BAL sampling. All
biopsies were taken from more than 2 lobes underwent histologic exam-
ination by an independent pathologist.
BOS Diagnosis and Classification
The mean of the 2 highest values measured at least 3 weeks apart post-
transplant were used to establish the baseline of FEV1 and the forced
expiratory flow between 25% and 75% of the vital capacity. BOS was
then classified according to the International Society for Heart and
Lung Transplantation Society guidelines as grade 0 if FEV1 90% and
forced expiratory flow between 25% and 75% of the vital capacity
75% of baseline, grade 1 if FEV1 was between 66% and 80%, grade
2 if FEV1 was between 51% and 65% and grade 3 if FEV1 was<50% of
baseline.1274 The Journal of Thoracic and Cardiovascular SurgDiagnosis of Rejection, Primary Graft Dysfunction,
and Infection
Rejection was diagnosed and graded histologically according to Inter-
national Society for Heart and Lung Transplantation Society scoring. Pa-
tients with acute rejection underwent steroid pulse therapy at 500 to
1000 mg/d for 3 days. If the patient was resistant to the steroid pulse ther-
apy, muromonab-CD3 (5mg/d for 7 days) or antithymocyte globulin (2mg/
kg bodyweight for 3-5 days) was administered. An episode of infection was
defined clinically and approved usingmicrobiologic, serologic, or histolog-
ic tests. CMV screening was performed by measurement of CMV serology
(quantitative polymerase chain reaction) and BAL. Bacterial and fungal
cultures as well as polymerase chain reaction for toxoplasmosis and pneu-
mocystis carinii were performed in each BAL. Colonization was defined if
the BAL microbiology was positive without histologic or clinical evidence
of infection. Primary graft dysfunction (PGD) was diagnosed based on the
radiologic findings and oxygenation index measured for all time points T0
through T72.14
Immunosuppression
The immunosuppression protocol has been described elsewhere.15
Briefly, patients received 1 g intravenous methylprednisolone intraopera-
tively, followed by 125 mg at 8, 16, and 24 hours postoperatively. There-
after, prednisolone was administered at 1 mg/kg/d and tapered to 0.25
mg/kg within 3 months. Some patients received rabbit antithymocyte glob-
ulin (Thymoglobuline, Sero-Merieux, Lion, France) 2 mg/kg intravenously
for the first 5 postoperative days. Mycophenolate mofetil (CellCept,
Hofmannn-La Roche, Switzerland) at 3 g/d was given intravenously on
the first postoperative days and then orally. Cyclosporine A (target level
350 ng/mL) or tacrolimus (target level 15  3 ng/mL) was administered
intravenously immediately after surgery, and was subsequently switched
to oral administration.
Recipients with BOS received steroid bolus therapy at 500 to 1000mg/d
for 3 days. Then the steroid was reduced to 1 mg/kg over 2 weeks, followed
by pulmonary function test and bronchoscopy. In case of BOS resistance,
the immunosuppression was changed as follows. Cyclosporine A was
switched to tacrolimus. If the switch in immunosuppression was not effec-
tive, the patients received extracorporeal photopheresis for 3 to 6 months
every second week 2 treatments, and since 2008 azithromycin 500 mg
33 weekly for a minimum of 3 months.
Enzyme-Linked Immunosorbent Assay
MicroVue YKL-40 enzyme immunoassay kit (Quidel, San Diego, Calif)
was used according to the manufacturer’s protocol to detect serumYKL-40
concentrations. Standard or serum samples were added to each streptavidin
and biotinylated murine anti-YKL-40 monoclonal antibody precoated
wells and incubated for 1 hour at room temperature. Furthermore, Quanti-
kine ELISA Kits (R&D Systems, Minneapolis, Minn) were used according
to themanufacturer’s protocol to detect serum concentrations of interleukin
(IL)-2, IL-4, IL-6, IL-10, IL-13, transforming growth factor-b, and inter-
feron-g. The substrate reaction was quantified spectrophotometrically by
using a Multiskan FC mircoplate photometer (Thermo Scientific, Austria)
at 450 nm as described previously.14
Statistical Analysis
All parameters were compared between patient groups by c2 test, t test,
and 1-way analysis of variance (ANOVA) or Tukey post hoc test according
to the scale of the variable (categorical or continuous). In case of skewed
data, a nonparametric test (Mann-WhitneyU test) was applied.Multiple lo-
gistic regression analysis evaluated the confounder-adjusted effects of
serum YKL-40 in relation to BOS, including all variables that were signif-
icant in univariate logistic regression analyses at the .05 level. The resulting
odd ratios (ORs) refer to a nanogram increase in YKL-40 concentrations.
The receiver operating characteristic (ROC) curve analyses were used toery c July 2014
TABLE 1. Demographic and clinical characteristics of study patients
All patients (N ¼ 142)
Bronchiolitis obliterans syndrome
Grade 0 (n ¼ 85) Grade 1 (n ¼ 25) Grade 2 (n ¼ 15) Grade 3 (n ¼ 17)
Mean age, y 51  13 49  13 57  8 53  13 50  14
Sex, male 79 (56) 44 (52) 14 (56) 9 (60) 12 (70)
Lung transplant type
Single 25 12 4 6 3
Double 117 73 21 9 14
Mean ischemic time, min 322  41 310  41 315  20 339  65 340  61
Time to bronchiolitis obliterans
syndrome/blood sampling, mo
16  9 15  8 (blood sampling) 11  11 10  5 23  12
Mechanical ventilation, d 4  4 3.9  4 3.8  4 3  1 7.8  2*
Intensive care unit stay, d 8  5 7  4 9  4 5  2 14  6*
FEV1 at discharge,% 54  26 58  25 52  22 48  17 36  27*
Peak 66 60 66 58 56
Primary graft dysfunction grade
0 88 (62) 60 (71) 13 (52) 8 (54) 7 (41)
1 31 (22) 20 (24) 5 (20) 3 (20) 3 (18)
2 13 (9) 3 (3) 5 (20) 2 (13) 3 (18)y
3 10 (7) 2 (2) 2 (8) 2 (13) 4 (23)y
Bacterial infection 28 22 1 4 1
Fungal infection 24 19 2 1 2
CMV infection 13 8 1 2 2
Acute rejection
A0 100 71 (83.5) 17 (68) 5 (33.3) 7 (41)
A1 29 12 (14.1) 6 (24) 7 (46.7)y 4 (23.5)
A2 9 2 (2.4) 2 (8) 3 (20)y 2 (11.8)y
A3 4 0 0 0 4 (23.5)y
B0 30 19 (22.4) 7 (28) 1 (6.7) 3 (17.6)
B1 80 56 (65.9) 13 (52) 6 (40) 5 (29.4)
B2 19 9 (10.6) 3 (12) 5 (33)y 2 (11.8)
B3 13 1 (1.2) 2 (8)y 3 (20)y 7 (41.2)y
Values are given as mean standard deviation or n (%). FEV1, Forced expiratory volume in 1 second; CMV, cytomegalovirus. *P¼ .02 versus bronchiolitis obliterans syndrome
grade 0. yP<.001 versus bronchiolitis obliterans syndrome grade 0.
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Xfind optimal cutoff levels for YKL-40 as the values that minimize the dis-
tance between the ROC curve and the upper left corner of the panel.
Repeated measures ANOVA was used to examine the changes of serum
YKL-40 concentrations over time. All statistical analyses were performed
using SAS system for Windows, version 9.1.3 and the Enterprise Guide,
version 4.1 (SAS Institute, Inc, Cary, NC). Results are expressed as
mean  standard deviation.RESULTS
Patient Clinical Characteristics
In our study cohort, 17 patients had BOS 3, 15 BOS 2, 25
BOS 1, and 85 patients had no BOS (grade 0). The FEV1 at
discharge from hospital was significantly lower in patients
who developed BOS grade 3 later compared with those
who did not (P ¼ .02) (Table 1). Posttransplant, recipients
who were destined to develop BOS grade 3 needed longer
mechanical ventilation (P ¼ .03) and intensive care unit
stay (P ¼ .02) compared with those who remained free of
BOS. During the posttransplant course BOS grade 2 and 3
patients had significantly more acute rejection episodes
compared with patients without BOS (P<.001) (Table 1).The Journal of Thoracic and CaOf notice, BOS (grades 1-3) was significantly associated
with PGD following lung transplantation (P ¼ .04)
(Table 1). However, the frequency of CMV, bacterial infec-
tions, and fungal infections was not significantly different
between patients with and without BOS.Elevated Pretransplant Serum YKL-40
Concentrations are Associated With BOS
Development
Pretransplant serum YKL-40 concentrations were higher
in lung recipients compared with healthy controls (P<.002)
(Figure 1, A). In addition, pretransplant serumYKL-40 con-
centrations were higher in patients who developed BOS
grade 1 (P<.0001) (Figure 1, A), 2 (P<.0001) (Figure 1,
A), and 3 (P< .0001) (Figure 1, A) compared with those
who belonged to BOS grade 0 group or healthy controls.
Pretransplant serum YKL-40 concentrations were higher
in patients with BOS grade 3 and 2 compared with BOS
grade 1 (P<.0001) (Figure 1, A). In addition, pretransplant
serum YKL-40 concentrations were not significantlyrdiovascular Surgery c Volume 148, Number 1 275
FIGURE 1. Pretransplant serum human chitinase-like glycoprotein YKL-40 concentrations predict bronchiolitis obliterans syndrome (BOS). A, Pretrans-
plant serum YKL-40 concentrations were elevated in patients with BOS grade 2 and 3 compared with BOS grade 1 and grade 0. All lung allograft recipients
had higher YKL-40 concentrations compared with healthy controls. B, At an optimal cut-off level of 109 ng/mL, pretransplant serumYKL-40 predicts BOS
development with a sensitivity of 85% and specificity of 82%. C, At an optimal cut-off level of 268 ng/mL, pretransplant serum YKL-40 predicts the devel-
opment of BOS grades 3 with a sensitivity of 76% and specificity of 82%. AUC, Area under the curve. *P ¼ .0001 versus BOS grade 1. yP<.0001 versus
BOS grade 0 or healthy controls.
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Xdifferent when patients with BOS grade 0 were compared
with healthy controls. Likewise, YKL-40 concentrations
were not significantly different when patients with BOS
grade 2 and 3 were compared (Figure 1, A). Univariate
logistic regression analysis revealed that pretransplant
serum YKL-40 concentrations are associated with BOS
development (OR, 1.64; 95% confidence interval,276 The Journal of Thoracic and Cardiovascular Surg1.04-2.09; P<.0001) (Table 2). Multivariate logistic regres-
sion suggested that elevated YKL-40 concentrations are
associated with BOS development (OR, 1.3; 95% confi-
dence interval, 1.01-1.9;P¼ .02). ROC curve analyses indi-
cated that pretransplant serumYKL-40 at an optimal cut-off
level of 109 ng/mL identifies the development of BOS
grades 1 through 3 with a sensitivity of 85% and specificityery c July 2014
TABLE 2. Logistic regression analysis in 142 patients indicating that pretransplant serum human chitinase-like glycoprotein YKL-40 levels
predict bronchiolitis obliterans syndrome development
Univariate OR (95% CI) P value Adjusted OR (95% CI) P value
Pretransplant YKL-40 1.64 (1.04-1.09) .0001 1.3 (1.01-1.9) .02
Age, y 1.03 (1-1.06) .05
Sex 0.81 (0.4-1.63) .55
Indication of LTX 0.98 (0.72-1.34) .89
Type of LTX 0.54 (0.18-1.58) .26
ICU stay, d 1.02 (0.95-1.1) .52
Mechanical ventilation, d 0.98 (0.84-1.16) .87
FEV1 at discharge 1.08 (0.97-1.21) .16
PGD 1.91 (1.12-3.25) .017 0.71 (0.14-3.7) .68
Time posttransplant, mo 1.12 (1.04-1.18) .001 1.13 (0.95-1.35) .16
Acute rejection
Grade A 4.13 (1.8-9.6) .001 4.1 (0.91-32.1) .11
Grade B 2.6 (1.5-4.55) .001 0.11 (0.03-3.98) .23
Bacterial infection 0.59 (0.22-1.53) .27
Fungal infection 0.21 (0.06-0.77) .02 0.01 (0.01-1.8) .07
OR, Odds ratio; CI, confidence interval; ICU, intensive care unit; LTX, lung transplantation; FEV1, forced expiratory volume in one second; PGD, primary graft dysfunction.
Jaksch et al Cardiothoracic Transplantationof 82% (area under the curve, 0.84; P<.0001) (Figure 1,
B). Furthermore, at an optimal cut-off level of 268 ng/mL,
pretransplant serum YKL-40 identifies the development of
BOS grades 3 with a sensitivity of 76% and specificity of
82% (area under the curve, 0.82; P<.0001) (Figure 1, C).T
XBOS Patients are Associated With Higher Serum
YKL-40 Concentrations
Posttransplant serum YKL-40 concentrations at the time
of BOS diagnosis were significantly elevated in patients
with BOS grades 1 to 3 compared with no BOS or healthy
controls (P< .02 and P< .0001, respectively) (Figure 2,
A). One-way ANOVA analysis suggested that serum
YKL-40 concentrations are significantly different between
BOS grades (P<.0001) (Figure 2, A). Specifically, serum
YKL-40 concentrations were significantly higher in patients
with BOS grades 3 (P< .01) (Figure 2, A), 2 (P ¼ .04)
(Figure 2, A), and 1 (P ¼ .04) (Figure 2, A) compared with
those with grade 0. Patients with BOS grade 0 had elevated
serum YKL-40 concentrations compared with healthy con-
trols (P<.0001) (Figure 2, A). In addition, serum YKL-40
concentrations were significantly higher in patients with
BOS grades 1 to 3 (P< .009) (Figure 2, B) at 3 months
post-BOS diagnosis compared with those with no BOS
(whose serum samples were obtained at a comparable time
point regarding time from transplant). Moreover, YKL-40
concentrations were not significantly different when BOS
grades were compared with each other (Figure 2, B).
Repeatedmeasures ANOVA revealed that therewere no sig-
nificant changes of serum YKL-40 concentrations over time
in all patients, regardless of presence of BOS (Figure 2, C).
Similar toYKL-40 serumfindings, BALYKL-40 concentra-
tions measured at BOS diagnosis were significantly higherThe Journal of Thoracic and Cain patients with BOS grades 1 to 3 than in those with no
BOS (P<.02) (Figure 2,D). However, no significant differ-
ences were found in the BALYKL-40 concentrations when
BOS grades were compared with each other.YKL-40 in Relation to Clinical and Procedure
Characteristics
Pretransplant serum YKL-40 concentrations were
slightly but not significantly elevated in patients with idio-
pathic pulmonary fibrosis (173.8  104 ng/mL) and cystic
fibrosis (165.9  105 ng/mL) compared with those with
chronic obstructive pulmonary disease (141.6  91
ng/mL) and pulmonary hypertension (145.2  108
ng/mL) (Figure 3, A). Pretransplant serum YKL-40 concen-
trations were significantly elevated in patients who devel-
oped PGD (pooled grades 1-3) compared with those with
PGD grade 0 (P ¼ .02); however, the differences were not
significantly different among PGD grades 1 to 3 (Figure 3,
B). There was no statistically significant difference in serum
YKL-40 concentrations in patients undergoing single lung
transplant compared with double lung recipients. There
was no significant association between serum YKL-40
concentrations and recipient age, sex, bacterial or fungal
infection, and frequency of acute rejection episodes.
Moreover, serum concentrations of IL-2 (P ¼ .02), IL-4
(P ¼ .02), IL-13 (P ¼ .04), and interferon-g (P ¼ .04)
measured at BOS diagnosis were significantly elevated
and correlated with YKL-40 levels in patients with BOS
compared with those with no BOS (Figure 3, C).DISCUSSION
The pathogenesis of BOS is not clearly understood; how-
ever, the existing evidence on the role of small airwayrdiovascular Surgery c Volume 148, Number 1 277
FIGURE 2. Elevated posttransplant serum human chitinase-like glycoprotein YKL-40 concentrations are associated with bronchiolitis obliterans syn-
drome (BOS). A, Serum YKL-40 concentrations at BOS diagnosis are significantly elevated in patients with BOS grades 1 to 3 compared with matched
patients without BOS (no-BOS). All lung allograft recipients have elevated serum YKL-40 concentrations compared with healthy controls. B, Serum
YKL-40 concentrations at 3months post-BOS diagnosis are significantly higher in patients with BOS grades 1 to 3 comparedwithmatched no-BOS patients.
C, Repeated measures analysis of variance indicates no significant changes of serum YKL-40 concentrations over time in all patients, regardless of presence
of BOS. D, YKL-40 concentrations at BOS diagnosis are higher in bronchoalveolar lavage of patients with BOS (grades 1-3) compared with matched
no-BOS patients. *P< .04 versus BOS grade 0; **P< .009 versus BOS grade 0; yP< .0001 versus healthy control. #P< .01 versus BOS grade 0;
zP ¼ .02 versus BOS grade 0.
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Xinflammation and acute rejection in BOS strongly suggests
that the cellular and humoral storm directed to the allograft
is crucial in the pathogenesis of BOS.6 Toward this end, we
and others have shown that several growth factors and cyto-
kines are involved in BOS pathogenesis.8,15-17 Our study
shows that YKL-40 is elevated in BOS patients and its levels278 The Journal of Thoracic and Cardiovascular Surgwell correlate with BOS severity. Although the function of
chitinases and chitinase-like proteins, including YKL-40,
in mammals is not clearly understood, evidence suggests
possible function of YKL-40 in immunologic response,
especially T helper 2-induced inflammation and tissue re-
modeling.13,18 It has been shown that YKL-40 is implicatedery c July 2014
FIGURE 3. Pretransplant serum human chitinase-like glycoprotein YKL-40 and inflammatory cytokines in relation to clinical characteristics. A, Pretrans-
plant serum YKL-40 concentrations are not significantly different in regard to the underlying pulmonary disease. B, Serum YKL-40 concentrations are
significantly higher in patients with primary graft dysfunction (PGD) compared with those without PGD. C, Serum concentrations of interleukin (IL)-2,
IL-4, IL-13, and interferon (IFN)-g measured at bronchiolitis obliterans syndrome (BOS) diagnosis were significantly elevated in patients with BOS
compared with those without BOS. COPD, Chronic obstructive pulmonary disease; PAH, pulmonary artery hypertension; CF, cystic fibrosis; LF, lung
fibrosis; TGFb, transforming growth factor-b. *P ¼ .02. yP ¼ .04.
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Xin the suppression of inflammatory cell apoptosis and the
elaboration of T helper 2 cytokines, including IL-4 and
IL-13.13,18 Furthermore, YKL-40 was also shown to stimu-
late alveolar macrophages and fibroblasts to release inflam-
matory and fibrogenic mediators such as IL-8, monocyte
chemotactic protein-1, macrophage inflammatory protein-
1-a, and matrix metalloproteinase-9.19,20 In line with that,
we and others have shown that matrix metalloproteinase-
9, IL-4, and IL-8 are associated with BOS.16,17The Journal of Thoracic and CaFurthermore, lung experimental models indicate that
YKL-40 contributes to the recruitment of eosinophils,
CD4þ lymphocytes, and alternatively activated macro-
phages, suggesting that YKL-40 is not only associated
with the T helper 2 response but also with other inflamma-
tory cellular responses in lung.13 With regard to tissue re-
modeling, it has been shown that YKL-40 stimulates the
mitogenesis of fibroblasts directly and indirectly by
enhancing the elaboration of IL-13.13 Reportedly, IL-13 isrdiovascular Surgery c Volume 148, Number 1 279
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Xidentified as a key mediator of lung tissue fibrosis that in-
duces epithelial cell apoptosis and stimulates profibrotic
gene expression in lung fibroblasts.13,21,22 However, the
role of IL-13 in BOS remains controversial.23-25 Taken
together, the association of YKL-40 with different inflam-
matory processes that contribute to BOS together with its
elevated levels found in the BOS patient cohort justifies
the assumption that YKL-40 is involved in BOS pathogen-
esis. However, the exact mechanism by which YKL-40
contributes to BOS calls for experimental study.
Another key finding of our study is that circulating pre-
transplant YKL-40 is associated with BOS development.
Serum YKL-40 concentrations could be therefore used to
identify patients at higher risk for development of BOS.
This approach could be beneficial in that it would allow pre-
ventive measures in high-risk patients and it offers the pos-
sibility of a tailored treatment in those lung allograft
recipients with elevated serum levels of YKL-40. Such pre-
ventive and therapeutic measures could alternatively use the
YKL-40 pathway to develop novel agents specifically
acting to mediate YKL-40 effects.
We have recently reported that serum ET-1 can serve as
an independent and noninvasive serum biomarker for the
early prediction of BOS; however, serum ET-1 was also
associated with acute allograft rejection.8 Interestingly,
serum YKL-40 was not associated with acute rejection ep-
isodes in the posttransplant course of the recipient cohort
studied here. One explanation might be that acute allograft
rejection is considered to be a mainly type-1 immune
response to the donor antigens.24,26 However, BOS is
believed to be due type-2 immune response, in which
YKL-40 is reportedly involved.13,26 Of notice, YKL-40
was associated with PGD in our study cohort; however,
this association was not significant in multivariate anal-
ysis. One explanation might be that YKL-40 is associated
with PGD as a risk factor for BOS but not involved in its
pathogenesis. Serum YKL-40 could therefore serve as an
easy measurable, specific, and independent marker
that could identify patients at high risk for BOS. Those
patients might be considered for close follow-up and
early adaptation of immunosuppression regimen when
indicated.Study Limitations
The major limitation of our study is that serum YKL-40
concentrations were measured at 3 time points. Studies us-
ing temporal posttransplant YKL-40 serum level changes
would be more conclusive. This limitation is hard to over-
come because the clinical condition of patients with BOS,
especially in those with higher BOS grades, does not allow
repeated invasive tests (eg, bronchoscopy). In addition,
compliance of such patients is often a further limiting factor
in close surveillance.280 The Journal of Thoracic and Cardiovascular SurgFinally, many foreign patients receiving a transplant at
our center remain in surveillance in their home countries
and are thus not available for follow-up studies.References
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